Evidence map›Paper›PMID 26439313›Full record

ArticleExperimental neurology2016

Ziram, a pesticide associated with increased risk for Parkinson's disease, differentially affects the presynaptic function of aminergic and glutamatergic nerve terminals at the Drosophila neuromuscular junction.

Ciara A Martin, Katherine M Myers, Audrey Chen, Nathan T Martin, Angel Barajas, Felix E Schweizer, David E Krantz

Open access · greenAbstract read
In one paragraph

Article in Experimental neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Dopamine Transporter Is a Master Regulator of Dopaminergic Neural Network Connectivity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ciara A MartinDepartment of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, United States; UCLA Interdepartmental Program in Molecular Toxicology, Los Angeles, CA 90095, United States. Electronic address: martin.ciaraann@gmail.com.
Katherine M MyersDepartment of Neurobiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, United States; UCLA Interdepartmental Program for Neuroscience, Los Angeles, CA 90095, United States. Electronic address: kmm2318@ucla.edu.
Audrey ChenDepartment of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, United States; Department of Neurobiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, United States. Electronic address: audchen@caltech.edu.
Nathan T MartinUCLA Biomedical Physics Interdepartmental Graduate Program, Los Angeles, CA 90095, United States. Electronic address: nathan.martin48@gmail.com.
Angel BarajasDepartment of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, United States. Electronic address: a.barajas40@gmail.com.
Felix E SchweizerDepartment of Neurobiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, United States; UCLA Interdepartmental Program for Neuroscience, Los Angeles, CA 90095, United States. Electronic address: felixs@ucla.edu.
David E KrantzDepartment of Psychiatry and Biobehavioral Sciences, Hatos Center for Neuropharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, United States; UCLA Interdepartmental Program in Molecular Toxicology, Los Angeles, CA 90095, United States; UCLA Interdepartmental Program for Neuroscience, Los Angeles, CA 90095, United States. Electronic address: dkrantz@ucla.edu.
University of California, Los Angeles · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA MSD ProgramR25GM055052 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BARBER, PAUL HENRY, HASSON, TAMA W. · 1996 to 2021
$9.2M
Project 4: Pesticides and Genes In PD: Studies In HumansP01ES016732 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHESSELET, MARIE-FRANCOISE S · 2008 to 2012
$6.7M
Training in Molecular ToxicologyT32ES015457 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALLARD, PATRICK, HANKINSON, OLIVER NMN · 2008 to 2025
$4.0M
Environmental toxin interactions with genetic risks for Parkinson's diseaseR01ES015747 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KRANTZ, DAVID EVAN · 2007 to 2011
$2.1M
The Influence of Neurotransmitter Transport on Aminergic NeuromodulationR01MH107390 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KRANTZ, DAVID EVAN · 2015 to 2019
$1.9M
Trafficking of the Drosophila Vesicular Monoamine TransporterR01MH076900 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KRANTZ, DAVID EVAN · 2007 to 2011
$1.5M
Identification of the Kenyon Cell NeurotransmitterR21ES024113 · NIEHS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KRANTZ, DAVID EVAN · 2016 to 2017
$424k
Ubiquitination as an acute regulator of synaptic transmissionR21NS075506 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCHWEIZER, FELIX E · 2011 to 2012
$424k
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1TR000124NIEHS NIH HHS ES016732NIEHS NIH HHS P01 ES016732NIEHS NIH HHS R01 ES015747NIEHS NIH HHS R01-ES015747NIEHS NIH HHS R21 ES024113NIEHS NIH HHS T32 ES015457NIGMS NIH HHS R25 GM055052NIMH NIH HHS R01 MH076900NIMH NIH HHS R01-MH076900NIMH NIH HHS R01 MH107390NINDS NIH HHS R21 NS075506NINDS NIH HHS R21-NS075506
6 · The paper itself

Abstract

Multiple populations of aminergic neurons are affected in Parkinson's disease (PD), with serotonergic and noradrenergic loci responsible for some non-motor symptoms. Environmental toxins, such as the dithiocarbamate fungicide ziram, significantly increase the risk of developing PD and the attendant spectrum of both motor and non-motor symptoms. The mechanisms by which ziram and other environmental toxins increase the risk of PD, and the potential effects of these toxins on aminergic neurons, remain unclear. To determine the relative effects of ziram on the synaptic function of aminergic versus non-aminergic neurons, we used live-imaging at the Drosophila melanogaster larval neuromuscular junction (NMJ). In contrast to nearly all other studies of this model synapse, we imaged presynaptic function at both glutamatergic Type Ib and aminergic Type II boutons, the latter responsible for storage and release of octopamine, the invertebrate equivalent of noradrenalin. To quantify the kinetics of exo- and endo-cytosis, we employed an acid-sensitive form of GFP fused to the Drosophila vesicular monoamine transporter (DVMAT-pHluorin). Additional genetic probes were used to visualize intracellular calcium flux (GCaMP) and voltage changes (ArcLight). We find that at glutamatergic Type Ib terminals, exposure to ziram increases exocytosis and inhibits endocytosis. By contrast, at octopaminergic Type II terminals, ziram has no detectable effect on exocytosis and dramatically inhibits endocytosis. In contrast to other reports on the neuronal effects of ziram, these effects do not appear to result from perturbation of the Ubiquitin Proteasome System (UPS) or calcium homeostasis. Unexpectedly, ziram also caused spontaneous and synchronized bursts of calcium influx (measured by GCaMP) and electrical activity (measured by ArcLight) at aminergic Type II, but not glutamatergic Type Ib, nerve terminals. These events are sensitive to both tetrodotoxin and cadmium chloride, and thus appear to represent spontaneous depolarizations followed by calcium influx into Type II terminals. We speculate that the differential effects of ziram on Type II versus Type Ib terminals may be relevant to the specific sensitivity of aminergic neurons in PD, and suggest that changes in neuronal excitability could contribute to the increased risk for PD caused by exposure to ziram. We also suggest that the fly NMJ will be useful to explore the synaptic effects of other pesticides associated with an increased risk of PD.

Indexed as

AnimalsDopamineDrosophila melanogasterEndocytosisExocytosisFungicides, IndustrialGlutamic AcidNeuromuscular JunctionParkinson DiseasePresynaptic TerminalsZiramDopamineFungicides, IndustrialGlutamic AcidZiramDithiocarbamateDopamineDrosophilaFungicideNeuronal excitabilityOctopamineParkinson's diseasePesticideZiram

Identifiers

PMID26439313
PMCPMC4688233
OpenAlexW1957897906

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.